Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non-Current Liabilities (2016 - 2025)

Ani Pharmaceuticals' Other Non-Current Liabilities history spans 12 years, with the latest figure at $12.2 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 110.41% year-over-year to $12.2 million; the TTM value through Dec 2025 reached $12.2 million, up 110.41%, while the annual FY2025 figure was $12.2 million, 110.41% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $12.2 million at Ani Pharmaceuticals, up from $11.3 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $35.1 million in Q4 2022 and bottomed at $1.5 million in Q3 2022.
  • The 5-year median for Other Non-Current Liabilities is $11.6 million (2024), against an average of $14.4 million.
  • The largest YoY upside for Other Non-Current Liabilities was 607.77% in 2023 against a maximum downside of 84.72% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $31.0 million in 2021, then increased by 13.09% to $35.1 million in 2022, then crashed by 66.58% to $11.7 million in 2023, then tumbled by 50.67% to $5.8 million in 2024, then soared by 110.41% to $12.2 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Other Non-Current Liabilities are $12.2 million (Q4 2025), $11.3 million (Q3 2025), and $18.1 million (Q2 2025).